4.
Wong AN, McArthur GA, Hofman MS, Hicks RJ. The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. Eur J Nucl Med Mol Imaging. 2017;
https://doi.org/10.1007/s00259-017-3691-7.
6.
Danielsen M, Kjaer A, Wu M, Martineau L, Nosrati M, Leong SP, et al. Prediction of positron emission tomography/computed tomography (PET/CT) positivity in patients with high-risk primary melanoma. Am J Nucl Med Mol Imaging. 2016;6:277–85.
PubMedPubMedCentral
8.
Acland KM, Healy C, Calonje E, O’Doherty M, Nunan T, Page C, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19:2674–8.
https://doi.org/10.1200/JCO.2001.19.10.2674.
CrossRef
11.
Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neuro-Oncol. 1999;44:275–81.
CrossRef
12.
Ghasemi M, Nabipour I, Omrani A, Alipour Z, Assadi M. Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis. Am J Nucl Med Mol Imaging. 2016;6:310–27.
PubMedPubMedCentral
13.
Valencak J, Heere-Ress E, Traub-Weidinger T, Raderer M, Schneeberger A, Thalhammer T, et al. Somatostatin receptor scintigraphy with 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-octreotide in patients with stage IV melanoma: in-vitro and in-vivo results. Melanoma Res. 2005;15:523–9.
CrossRefPubMed
14.
Hong H, Sun J, Cai W. Anatomical and molecular imaging of skin cancer. Clin Cosmet Investig Dermatol. 2008;1:1–17.
PubMedPubMedCentral
15.
Ren G, Pan Y, Cheng Z. Molecular probes for malignant melanoma imaging. Curr Pharm Biotechnol. 2010;11:590–602.
CrossRefPubMed
16.
d’Ischia M, Wakamatsu K, Cicoira F, Di Mauro E, Garcia-Borron JC, Commo S, et al. Melanins and melanogenesis: from pigment cells to human health and technological applications. Pigment Cell Melanoma Res. 2015;28:520–44.
https://doi.org/10.1111/pcmr.12393.
CrossRefPubMed
20.
Chezal JM, Papon J, Labarre P, Lartigue C, Galmier MJ, Decombat C, et al. Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma. J Med Chem. 2008;51:3133–44.
https://doi.org/10.1021/jm701424g.
CrossRefPubMed
21.
Link E, Lukiewicz S. A new radioactive drug selectively accumulating in Melanoma cells. Eur J Nucl Med. 1982;7:469–73.
CrossRefPubMed
22.
Link EM, Blower PJ, Costa DC, Lane DM, Lui D, Brown RS, et al. Early detection of melanoma metastases with radioiodinated methylene blue. Eur J Nucl Med. 1998;25:1322–9.
CrossRefPubMed
23.
Link EM, Carpenter RN. 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of cutaneous tumors and lymph node metastases. Cancer Res. 1992;52:4385–90.
PubMed
24.
Michelot JM, Moreau MF, Labarre PG, Madelmont JC, Veyre AJ, Papon JM, et al. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J Nucl Med: Off Publ Soc Nucl Med. 1991;32:1573–80.
27.
Sillaire-Houtmann I, Bonafous J, Veyre A, Mestas D, D’Incan M, Moins N, et al. Phase 2 clinical study of 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma. J Fr Ophtalmol. 2004;27:34–9.
CrossRefPubMed
28.
Michelot JM, Moreau MF, Veyre AJ, Bonafous JF, Bacin FJ, Madelmont JC, et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). J Nucl Med: Off Publ Soc Nucl Med. 1993;34:1260–6.
29.
Brandau W, Niehoff T, Pulawski P, Jonas M, Dutschka K, Sciuk J, et al. Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma. J Nucl Med: Off Publ Soc Nucl Med. 1996;37:1865–71.
31.
Dittmann H, Coenen HH, Zolzer F, Dutschka K, Brandau W, Streffer C. In vitro studies on the cellular uptake of melanoma imaging aminoalkyl-iodobenzamide derivatives (ABA). Nucl Med Biol. 1999;26:51–6.
CrossRefPubMed
32.
Bacin F, Michelot J, Bonafous J, Veyre A, Moreau MF, Kemeny JL, et al. Clinical study of [123I] N-(2-diethylaminoethyl)-4-iodobenzamide in the diagnosis of primary and metastatic ocular melanoma. Acta Ophthalmol Scand. 1998;76:56–61.
CrossRefPubMed
33.
Larisch R, Schulte KW, Vosberg H, Ruzicka T, Muller-Gartner HW. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo. J Nucl Med: Off Publ Soc Nucl Med. 1998;39:996–1001.
34.
Labarre P, Papon J, Moreau MF, Moins N, Veyre A, Madelmont JC. Evaluation in mice of some iodinated melanoma imaging agents using cryosectioning and multi-wire proportional counting. Eur J Nucl Med. 1999;26:494–8.
CrossRefPubMed
36.
Pham TQ, Berghofer P, Liu X, Greguric I, Dikic B, Ballantyne P, et al. Preparation and biologic evaluation of a novel radioiodinated benzylpiperazine, 123I-MEL037, for malignant melanoma. J Nucl Med: Off Publ Soc Nucl Med. 2007;48:1348–56.
https://doi.org/10.2967/jnumed.107.041673.
CrossRef
38.
Chang CC, Chang CH, Shen CC, Chen CL, Liu RS, Lin MH, et al. Synthesis and characterization of a novel radioiodinated phenylacetamide and its homolog as theranostic agents for malignant melanoma. Eur J Pharm Sci: Off J Eur Fed Pharm Sci. 2016;81:201–9.
https://doi.org/10.1016/j.ejps.2015.10.019.
CrossRef
39.
Cachin F, Miot-Noirault E, Gillet B, Isnardi V, Labeille B, Payoux P, et al. (123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial. J Nucl Med: Off Publ Soc Nucl Med. 2014;55:15–22.
https://doi.org/10.2967/jnumed.113.123554.
CrossRef
40.
Bonnet-Duquennoy M, Papon J, Mishellany F, Labarre P, Guerquin-Kern JL, Wu TD, et al. Targeted radionuclide therapy of melanoma: anti-tumoural efficacy studies of a new 131I labelled potential agent. Int J Cancer J Int Cancer. 2009;125:708–16.
https://doi.org/10.1002/ijc.24413.
CrossRef
41.
Billaud EM, Maisonial-Besset A, Rbah-Vidal L, Vidal A, Besse S, Bequignat JB, et al. Synthesis, radiolabeling and preliminary in vivo evaluation of multimodal radiotracers for PET imaging and targeted radionuclide therapy of pigmented melanoma. Eur J Med Chem. 2015;92:818–38.
https://doi.org/10.1016/j.ejmech.2015.01.034.
CrossRefPubMed
42.
Degoul F, Borel M, Jacquemot N, Besse S, Communal Y, Mishellany F, et al. In vivo efficacy of melanoma internal radionuclide therapy with a 131I-labelled melanin-targeting heteroarylcarboxamide molecule. Int J Cancer J Int Cancer. 2013;133:1042–53.
https://doi.org/10.1002/ijc.28103.
CrossRef
43.
Billaud EM, Rbah-Vidal L, Vidal A, Besse S, Tarrit S, Askienazy S, et al. Synthesis, radiofluorination, and in vivo evaluation of novel fluorinated and iodinated radiotracers for PET imaging and targeted radionuclide therapy of melanoma. J Med Chem. 2013;56:8455–67.
https://doi.org/10.1021/jm400877v.
CrossRefPubMed
48.
Greguric I, Taylor SR, Denoyer D, Ballantyne P, Berghofer P, Roselt P, et al. Discovery of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance. J Med Chem. 2009;52:5299–302.
https://doi.org/10.1021/jm9008423.
CrossRefPubMed
51.
Rbah-Vidal L, Vidal A, Besse S, Cachin F, Bonnet M, Audin L, et al. Early detection and longitudinal monitoring of experimental primary and disseminated melanoma using [(1)(0)F]ICF01006, a highly promising melanoma PET tracer. Eur J Nucl Med Mol Imaging. 2012;39:1449–61.
https://doi.org/10.1007/s00259-012-2168-y.
CrossRefPubMed
54.
Denoyer D, Potdevin T, Roselt P, Neels OC, Kirby L, Greguric I, et al. Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration. J Nucl Med: Off Publ Soc Nucl Med. 2011;52:115–22.
https://doi.org/10.2967/jnumed.110.078154.
CrossRef
60.
Belhocine TZ, Scott AM, Even-Sapir E, Urbain JL, Essner R. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med: Off Publ Soc Nucl Med. 2006;47:957–67.
61.
Unterrainer M, Galldiks N, Suchorska B, Kowalew LC, Wenter V, Schmid-Tannwald C, et al. 18F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis. J Nucl Med: Off Publ Soc Nucl Med. 2017;58:584–9.
https://doi.org/10.2967/jnumed.116.180075.
CrossRef
62.
Valdes Olmos RA, Vidal-Sicart S, Manca G, Mariani G, Leon-Ramirez LF, Rubello D, et al. Advances in radioguided surgery in oncology. Q J Nucl Med Mol Imaging: Off Publ Ital Assoc Nucl Med (AIMN) [and] Int Assoc Radiopharmacology (IAR), [and] Sect So. 2017;61:247–70.
10.23736/S1824-4785.17.02995-8.
CrossRef
63.
Bronstein Y, Ng CS, Rohren E, Ross MI, Lee JE, Cormier J, et al. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. AJR Am J Roentgenol. 2012;198:902–8.
https://doi.org/10.2214/AJR.11.7280.
CrossRefPubMed
64.
Garg S, Kothari K, Thopate SR, Doke AK, Garg PK. Design, synthesis, and preliminary in vitro and in vivo evaluation of N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide ([18F]-DAFBA): a novel potential PET probe to image melanoma tumors. Bioconjug Chem. 2009;20:583–90.
https://doi.org/10.1021/bc8005094.
CrossRefPubMedPubMedCentral
66.
Denoyer D, Greguric I, Roselt P, Neels OC, Aide N, Taylor SR, et al. High-contrast PET of melanoma using (18)F-MEL050, a selective probe for melanin with predominantly renal clearance. J Nucl Med: Off Publ Soc Nucl Med. 2010;51:441–7.
https://doi.org/10.2967/jnumed.109.070060.
CrossRef
67.
Xie L, Yui J, Fujinaga M, Hatori A, Yamasaki T, Kumata K, et al. Molecular imaging of ectopic metabotropic glutamate 1 receptor in melanoma with a positron emission tomography radioprobe (18) F-FITM. Int J Cancer J Int Cancer. 2014;135:1852–9.
https://doi.org/10.1002/ijc.28842.
CrossRef
70.
Chen J, Cheng Z, Hoffman TJ, Jurisson SS, Quinn TP. Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res. 2000;60:5649–58.
PubMed
71.
Siegrist W, Oestreicher M, Stutz S, Girard J, Eberle AN. Radioreceptor assay for alpha-MSH using mouse B16 melanoma cells+. J Recept Res. 1988;8:323–43.
CrossRefPubMed
73.
Vaidyanathan G, Zalutsky MR. Fluorine-18-labeled [Nle4,D-Phe7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. Nucl Med Biol. 1997;24:171–8.
CrossRefPubMed
74.
Cowell SM, Balse-Srinivasan PM, Ahn JM, Hruby VJ. Design and synthesis of peptide antagonists and inverse agonists for G protein-coupled receptors. Methods Enzymol. 2002;343:49–72.
CrossRefPubMed
75.
Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77:5754–8.
CrossRefPubMedPubMedCentral
76.
Hruby VJ, Wilkes BC, Hadley ME, Al-Obeidi F, Sawyer TK, Staples DJ, et al. alpha-Melanotropin: the minimal active sequence in the frog skin bioassay. J Med Chem. 1987;30:2126–30.
CrossRefPubMed
77.
Giblin MF, Wang N, Hoffman TJ, Jurisson SS, Quinn TP. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Acad Sci U S A. 1998;95:12814–8.
CrossRefPubMedPubMedCentral
78.
Froidevaux S, Calame-Christe M, Tanner H, Eberle AN. Melanoma targeting with DOTA-alpha-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake. J Nucl Med: Off Publ Soc Nucl Med. 2005;46:887–95.
79.
Bednarek MA, Silva MV, Arison B, MacNeil T, Kalyani RN, Huang RR, et al. Structure-function studies on the cyclic peptide MT-II, lactam derivative of alpha-melanotropin. Peptides. 1999;20:401–9.
CrossRefPubMed
80.
Grieco P, Cai M, Liu L, Mayorov A, Chandler K, Trivedi D, et al. Design and microwave-assisted synthesis of novel macrocyclic peptides active at melanocortin receptors: discovery of potent and selective hMC5R receptor antagonists. J Med Chem. 2008;51:2701–7.
https://doi.org/10.1021/jm701181n.
CrossRefPubMedPubMedCentral
86.
Wei L, Butcher C, Miao Y, Gallazzi F, Quinn TP, Welch MJ, et al. Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med: Off Publ Soc Nucl Med. 2007;48:64–72.
95.
Nagy G, Denes N, Kis A, Szabo JP, Berenyi E, Garai I, et al. Preclinical evaluation of melanocortin-1 receptor (MC1-R) specific 68Ga- and 44Sc-labeled DOTA-NAPamide in melanoma imaging. Eur J Pharm Sci: Off J Eur Fed Pharm Sci. 2017;106:336–44.
https://doi.org/10.1016/j.ejps.2017.06.026.
CrossRef
97.
Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, et al. A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med: Off Publ Soc Nucl Med. 2004;45:116–23.
98.
Cheng Z, Zhang L, Graves E, Xiong Z, Dandekar M, Chen X, et al. Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog. J Nucl Med: Off Publ Soc Nucl Med. 2007;48:987–94.
https://doi.org/10.2967/jnumed.107.039602.
CrossRef
99.
Cheng Z, Chen J, Miao Y, Owen NK, Quinn TP, Jurisson SS. Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues. J Med Chem. 2002;45:3048–56.
CrossRefPubMed
100.
Miao Y, Benwell K, Quinn TP. 99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med: Off Publ Soc Nucl Med. 2007;48:73–80.
101.
Quinn T, Zhang X, Miao Y. Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues. G Ital Dermatol Venereol: Organo Ufficiale Soc Ital Dermatol Sifilografia. 2010;145:245–58.
109.
Hernandez R, Valdovinos HF, Yang Y, Chakravarty R, Hong H, Barnhart TE, et al. (44)Sc: an attractive isotope for peptide-based PET imaging. Molecular pharmaceutics. 2014;11:2954–2961. doi:
https://doi.org/10.1021/mp500343j.
115.
Jin ZH, Furukawa T, Kumata K, Xie L, Yui J, Wakizaka H, et al. Development of the Fibronectin-Mimetic Peptide KSSPHSRN(SG)5RGDSP as a Novel Radioprobe for Molecular Imaging of the Cancer Biomarker alpha5beta1 Integrin. Biol Pharm Bull. 2015;38:1722–31.
https://doi.org/10.1248/bpb.b15-00344.
CrossRefPubMed
118.
Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med: Off Publ Soc Nucl Med. 2005;46:1333–41.
119.
Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clini Cancer Res: Off J Am Assoc Cancer Res. 2006;12:3942–9.
https://doi.org/10.1158/1078-0432.CCR-06-0266.
CrossRef
125.
Zhai C, Summer D, Rangger C, Haas H, Haubner R, Decristoforo C. Fusarinine C, a novel siderophore-based bifunctional chelator for radiolabeling with Gallium-68. J Label Compd Radiopharm. 2015;58:209–14.
https://doi.org/10.1002/jlcr.3286.
CrossRef
127.
Petrik M, Zhai C, Novy Z, Urbanek L, Haas H, Decristoforo C. In Vitro and In Vivo Comparison of Selected Ga-68 and Zr-89 Labelled Siderophores. Mol Imaging Biol: MIB : Off Publ Acad Mol Imaging. 2016;18:344–52.
https://doi.org/10.1007/s11307-015-0897-6.
CrossRef
128.
Zhai C, Franssen GM, Petrik M, Laverman P, Summer D, Rangger C, et al. Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [(68)Ga]NODAGA-RGD-In Vivo Imaging Studies in Human Xenograft Tumors. Mol Imaging Biol: MIB: Off Publ Acad Mol Imaging. 2016;18:758–67.
https://doi.org/10.1007/s11307-016-0931-3.
CrossRef
129.
Eisenwiener KP, Prata MI, Buschmann I, Zhang HW, Santos AC, Wenger S, et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem. 2002;13:530–41.
CrossRefPubMed
130.
Simecek J, Schulz M, Notni J, Plutnar J, Kubicek V, Havlickova J, et al. Complexation of metal ions with TRAP (1,4,7-triazacyclononane phosphinic acid) ligands and 1,4,7-triazacyclononane-1,4,7-triacetic acid: phosphinate-containing ligands as unique chelators for trivalent gallium. Inorg Chem. 2012;51:577–90.
https://doi.org/10.1021/ic202103v.
CrossRefPubMed
133.
Neubauer S, Rechenmacher F, Beer AJ, Curnis F, Pohle K, D’Alessandria C, et al. Selective imaging of the angiogenic relevant integrins alpha5beta1 and alphavbeta3. Angew Chem (Int Engl). 2013;52:11656–9.
https://doi.org/10.1002/anie.201306376.
CrossRef
134.
Heckmann D, Meyer A, Laufer B, Zahn G, Stragies R, Kessler H. Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor. Chembiochem : Eur J Chem Biol. 2008;9:1397–407.
https://doi.org/10.1002/cbic.200800045.
CrossRef
135.
Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J Cell Biol. 1994;124:373–80.
CrossRefPubMed
137.
D’Alessandria C, Pohle K, Rechenmacher F, Neubauer S, Notni J, Wester HJ, et al. In vivo biokinetic and metabolic characterization of the (6)(8)Ga-labelled alpha5beta1-selective peptidomimetic FR366. Eur J Nucl Med Mol Imaging. 2016;43:953–63.
https://doi.org/10.1007/s00259-015-3218-z.
CrossRefPubMed
138.
Notni J, Steiger K, Hoffmann F, Reich D, Kapp TG, Rechenmacher F, et al. Complementary, Selective PET Imaging of Integrin Subtypes alpha5beta1 and alphavbeta3 Using 68Ga-Aquibeprin and 68Ga-Avebetrin. J Nucl Med: Off Publ Soc Nucl Med. 2016;57:460–6.
https://doi.org/10.2967/jnumed.115.165720.
CrossRef
139.
Notni J, Steiger K, Hoffmann F, Reich D, Schwaiger M, Kessler H, et al. Variation of Specific Activities of 68Ga-Aquibeprin and 68Ga-Avebetrin Enables Selective PET Imaging of Different Expression Levels of Integrins alpha5beta1 and alphavbeta3. J Nucl Med: Off Publ Soc Nucl Med. 2016;57:1618–24.
https://doi.org/10.2967/jnumed.116.173948.
CrossRef
140.
Bianchini F, Fabbrizzi P, Menchi G, Raspanti S, Bottoncetti A, Passeri A, et al. Radiosynthesis and micro-SPECT analysis of triazole-based RGD integrin ligands as non-peptide molecular imaging probes for angiogenesis. Bioorg Med Chem. 2015;23:1112–22.
https://doi.org/10.1016/j.bmc.2014.12.065.
CrossRefPubMed
151.
Flook AM, Yang J, Miao Y. Effects of amino acids on melanoma targeting and clearance properties of Tc-99m-labeled Arg-X-Asp-conjugated alpha-melanocyte stimulating hormone peptides. J Med Chem. 2013;56:8793–802.
https://doi.org/10.1021/jm4012356.
CrossRefPubMed
157.
Flook AM, Yang J, Miao Y. Substitution of the Lys linker with the beta-Ala linker dramatically decreased the renal uptake of 99mTc-labeled Arg-X-Asp-conjugated and X-Ala-Asp-conjugated alpha-melanocyte stimulating hormone peptides. J Med Chem. 2014;57:9010–8.
https://doi.org/10.1021/jm501114v.
CrossRefPubMedPubMedCentral
160.
Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet. 2003;34:108–12.
https://doi.org/10.1038/ng1148.
CrossRefPubMed
163.
Gelb T, Pshenichkin S, Rodriguez OC, Hathaway HA, Grajkowska E, DiRaddo JO, et al. Metabotropic glutamate receptor 1 acts as a dependence receptor creating a requirement for glutamate to sustain the viability and growth of human melanomas. Oncogene. 2015;34:2711–20.
https://doi.org/10.1038/onc.2014.231.
CrossRefPubMed
165.
Yamasaki T, Fujinaga M, Kawamura K, Yui J, Hatori A, Ohya T, et al. In vivo measurement of the affinity and density of metabotropic glutamate receptor subtype 1 in rat brain using 18F-FITM in small-animal PET. J Nucl Med: Off Publ Soc Nucl Med. 2012;53:1601–7.
https://doi.org/10.2967/jnumed.112.105908.
CrossRef
166.
Fujinaga M, Xie L, Yamasaki T, Yui J, Shimoda Y, Hatori A, et al. Synthesis and evaluation of 4-halogeno-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-[11C]methy lbenzamide for imaging of metabotropic glutamate 1 receptor in melanoma. J Med Chem. 2015;58:1513–23.
https://doi.org/10.1021/jm501845n.
CrossRefPubMed
179.
Xin Y, Cai H. Improved Radiosynthesis and Biological Evaluations of L- and D-1-[18F]Fluoroethyl-Tryptophan for PET Imaging of IDO-Mediated Kynurenine Pathway of Tryptophan Metabolism. Mol Imaging Biol: MIB : Off Publ Acad Mol Imaging. 2016;
https://doi.org/10.1007/s11307-016-1024-z.
184.
Nedrow JR, Josefsson A, Park S, Ranka S, Roy S, Sgouros G. Imaging of programmed death ligand-1 (PD-L1): impact of protein concentration on distribution of anti-PD-L1 SPECT agent in an immunocompetent melanoma murine model. J Nucl Med: Off Publ Soc Nucl Med. 2017;
https://doi.org/10.2967/jnumed.117.193268.
185.
Sharp PA. Ctr1 and its role in body copper homeostasis. Int J Biochem Cell Biol. 2003;35:288–91.
CrossRefPubMed
187.
Kim KI, Jang SJ, Park JH, Lee YJ, Lee TS, Woo KS, et al. Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model. J Nucl Med: Off Publ Soc Nucl Med. 2014;55:1692–8.
https://doi.org/10.2967/jnumed.114.141127.
CrossRef
188.
Peng F, Lu X, Janisse J, Muzik O, Shields AF. PET of human prostate cancer xenografts in mice with increased uptake of 64CuCl2. J Nucl Med: Off Publ Soc Nucl Med. 2006;47:1649–52.
194.
Rosenblum MG, Murray JL, Haynie TP, Glenn HJ, Jahns MF, Benjamin RS, et al. Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma. Cancer Res. 1985;45:2382–6.
PubMed
195.
Dadachova E, Moadel T, Schweitzer AD, Bryan RA, Zhang T, Mints L, et al. Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease. Cancer Biother Radiopharm. 2006;21:117–29.
https://doi.org/10.1089/cbr.2006.21.117.
CrossRefPubMed
196.
Dadachova E, Revskaya E, Sesay MA, Damania H, Boucher R, Sellers RS, et al. Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol Ther. 2008;7:1116–27.
CrossRefPubMed
198.
Revskaya E, Jongco AM, Sellers RS, Howell RC, Koba W, Guimaraes AJ, et al. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15:2373–9.
https://doi.org/10.1158/1078-0432.CCR-08-2376.
CrossRef
203.
Vavere AL, Butch ER, Dearling JL, Packard AB, Navid F, Shulkin BL, et al. 64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma. Journal of nuclear medicine : official publication. Soc Nucl Med. 2012;53:1772–8.
https://doi.org/10.2967/jnumed.112.104208.
CrossRef
210.
Vag T, Gerngross C, Herhaus P, Eiber M, Philipp-Abbrederis K, Graner FP, et al. First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers. J Nucl Med: Off Publ Soc Nucl Med. 2016;57:741–6.
https://doi.org/10.2967/jnumed.115.161034.
CrossRef
214.
Horsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Miederer M, et al. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up. Eur J Cancer. 2016;58:41–51.
https://doi.org/10.1016/j.ejca.2016.01.009.
CrossRefPubMed
217.
Camacho X, Calzada V, Fernandez M, Alonso O, Chammas R, Riva E, et al. 177Lu-DOTA-Bevacizumab: Radioimmunotherapy agent for melanoma. Curr Radiopharm. 2016.
221.
Viallard C, Perrot Y, Boudhraa Z, Jouberton E, Miot-Noirault E, Bonnet M, et al. [(1)(2)(3)I]ICF01012 melanoma imaging and [(1)(3)(1)I]ICF01012 dosimetry allow adapted internal targeted radiotherapy in preclinical melanoma models. Eur J Dermatol: EJD. 2015;25:29–35.
https://doi.org/10.1684/ejd.2014.2481.
CrossRefPubMed
222.
Mier W, Kratochwil C, Hassel JC, Giesel FL, Beijer B, Babich JW, et al. Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52. J Nucl Med: Off Publ Soc Nucl Med. 2014;55:9–14.
https://doi.org/10.2967/jnumed.112.112789.
CrossRef
224.
Maisonial A, Kuhnast B, Papon J, Boisgard R, Bayle M, Vidal A, et al. Single photon emission computed tomography/positron emission tomography imaging and targeted radionuclide therapy of melanoma: new multimodal fluorinated and iodinated radiotracers. J Med Chem. 2011;54:2745–66.
https://doi.org/10.1021/jm101574q.
CrossRefPubMed
226.
Rbah-Vidal L, Vidal A, Billaud EM, Besse S, Ranchon-Cole I, Mishellany F, et al. Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy. Neoplasia. 2017;19:17–27.
https://doi.org/10.1016/j.neo.2016.11.001.
CrossRefPubMed